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Role of Lipocalin 2 (LCN2) in cardiovascular remodeling induced by aldosterone M. Buonafine (1), A. Tarjus (1), B. Gravez (1), C. Amador (1), El Moghrabi (1), C. Latouche (1), P. Rossignol (2), F. Zannad (2), N. Farman (1), N. López-Andrés (3), F. Jaisser (1) (1) Inserm U1138 équipe 1, Centre de Recherches des Cordeliers, Paris, France -(2) Inserm U961, Faculté de Médecine, Vandoeuvre-lès-Nancy, France -(3) Centro de Investigacion Biomedica de Navarra, Pamplona, Spain Neutrophil Gelatinase Associated Lipocalin or Lipocalin 2 (LCN2) is a circulating protein, member of the lipocalin family, which binds MMP9 and modulates its stability and activity. We have recently shown that LCN2 is a primary target of aldosterone/mineralocorticoid receptor (MR) in endothelial cells, vascular smooth muscle cells and cardiomyocytes. We hypothesized that LCN2 could be a mediator of aldosterone/MR profibrotic and proinflammatory effects in the cardiovascular system. Wild type (WT) and LCN2 Knock Out (KO) mice were subjected to an uni-nephrectomy aldosterone salt challenge (NAS, 200μg/kg/day of aldo, 1% NaCl in tap water) for 4 weeks. Blood pressure (SBP) was measured by tail cuff method. Cardiovascular fibrosis and inflammation were analyzed by RT-PCR, western blot, immunohistochemistry and ELISA. There was no difference in SBP between transgenic mice compared to WT mice in basal condition. With NAS challenge, SBP was increased only in WT mice (SBP; CT 107±3, CT NAS 133±5, KO 109±3, KO NAS 115±3 mmHg). Quantification of pro collagen I N-terminal peptide (PINP) in plasma showed an increase of PINP due to NAS treatment in WT that was prevented by LCN2 inactivation (CT 83±15, CT NAS 129±10, KO 70±19, KO NAS 59±12 μg/l). In myocardium, NAS treatment increased collagen type I and perivascular fibrosis in WT whereas KO were resistant to fibrosis (Collagen Volume Fraction; CT 19±3, CT NAS 28±2, KO 20±3, KO NAS 20±3%). In aorta, collagen type I, vascular fibrosis and osteopontin were also increased by NAS in WT. These increases were prevented by LCN2 inactivation (CVF; CT 24±4, CT NAS 34±5, KO 21±2, KO NAS 28±2%). Our results show that LCN2 plays a key role in aldosterone/MRmediated vascular fibrosis and inflammation, but not in cardiac interstitial fibrosis and vascular dysfunction. We are now analyzing 1) the specificity of aldo/MR versus other pro-fibrotic challenges (AngII, catecholamines) as well as 2) the role of inflammation in the effects mediated by Lcn2.
Sympathetic overactivity: a very early manifestation of metabolic syndrome
Safir Habib (1), Philippe Van De Borne (2), Nathalie Niederhoffer (3), Erik Sauleau (4), Eliane Albuisson (5), Patrick Rossignol (5) Sympathetic overactivity is a hallmark of metabolic syndrome (MS). Data showing sympathetic overactivity in patients with early cardiovascular and metabolic disorders, i.e., prodromal forms of MS, are lacking. Sympathetic activity was measured by microneurography (MSNA), heart rate variability (HRV), blood pressure variability (BPV) and plasma and urinary catecholamines. β 2 -adrenergic receptor (β 2 -AR) and the G-protein coupled receptor kinase 2 (GRK2) mRNA expression levels were tested as possible markers of sympathetic activity in blood mononuclear cells (PBMCs). 40 healthy volunteers and 16 patients with established ( 3 components of the MS) and 23 incomplete (two components) MS were compared. MSNA was not only increased in patients with overt MS but also among patients with incomplete MS (P<0.001). In PBMCs of patients with incomplete MS, a significant 3.4 fold increase in the β 2 -AR over GRK2 mRNAs expression ratio was observed (P=0.001); this ratio correlated well with MSNA. ( Aim: To evaluate the impact of admission glycaemia in the short prognosis of diabetic and non-diabetic patients admitted for STEMI and to identify independent predictors of post-ACS mortality.
Population and methods:
This study included 567 patients admitted to a single coronary care unit for STEMI, between January 2004 and June 2012. Our population was divided in three groups according to the tertiles of glycaemia at admission (T1<7; T2=7-11 e T3>11 mmol/l). Rates of success after revascularisation, intrahospital mortality, and ventricular arrhythmias were collected Results: Hyperglycaemia at admission was associated to worse cardiovascular risk profile, more severe coronary disease (more 3 vessel disease), incomplete revascularization, higher creatinine levels and more life threatening ventricular arrhythmias (VT/VF). In the predefined tertiles, in-hospital mortality was 4%, 5.2% and 14% (p<0.001). Life threatening arrhythmias were respectively 2.4%; 4% and 9% (p:0.017). In the group of patients with glycemia >11 mmol/l (224 patients), outcomes were similar between the diabetic and non diabetic patients with death rates respectively 13.8% and 13.9% 
